Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916182 | 0.88 | ACSS2 (0.38) | GRM4ACSS2SREBF2MAPTKDM4E | |
| SCHEMBL916255 | 0.88 | SLC22A12 (0.45) | GRM4ACSS2SREBF2MAPTKDM4E | |
| SCHEMBL916140 | 0.87 | AURKA (0.40) | GRM4ACSS2SREBF2MAPTKDM4E | |
| SCHEMBL916272 | 0.87 | SLC22A12 (0.39) | HPGDALDH1A1GRM4ACSS2SREBF2 | |
| SCHEMBL916206 | 0.85 | GNRHR (0.39) | ALDH1A1POLBACSS2SREBF2MEN1 | |
| SCHEMBL916474 | 0.84 | IMPDH2 (0.40) | IMPDH2TTKARHPGDALDH1A1 | |
| SCHEMBL916127 | 0.84 | HPGD (0.36) | ARHPGDALDH1A1POLBGRM4 | |
| SCHEMBL917623 | 0.83 | F2 (0.36) | ARALDH1A1POLBMAPTKMT2A | |
| SCHEMBL917300 | 0.78 | CYP1A2 (0.40) | ARHPGDALDH1A1MEN1MAPT | |
| SCHEMBL916116 | 0.75 | ACSS2 (0.48) | ACSS2SREBF2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | IMPDH2 2572/4885TTK 4058/4885AR 2/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | IMPDH2 4438/4885TTK 4551/4885AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.